Shalby Limited
Shalby Ltd is engaged in healthcare delivery space in India. It operates a chain of multi-specialty hospitals across India. The business of the company is to offer tertiary and quaternary healthcare services to patients in various areas of specialization such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, renal transplantations, etc.The company is the global leader in knee replacement…
What Shalby files
- Others52
- Important50
- Investor Meet34
- Board Meeting8
- Updates7
- PPTs5
Shalby's Q3 FY26 consolidated revenue saw a slight dip of 0.6% year-on-year to ₹279.4 Cr. While consolidated PBT decreased by 25.3% to ₹9.2 Cr, PAT showed a strong recovery, surging to ₹1.3 Cr from a previous loss. The implant (MedTech) business was a key highlight, with revenue growing 29% year-on-year...
Here's a concise summary of Shalby's investor presentation for Q2 FY26: **1. Business Performance:** Shalby reported solid Q2 FY26 results with consolidated revenue up 5.5% YoY to ₹289.9 Cr and PBT jumping 39.2% YoY to ₹19.1 Cr. PAT saw a significant 208.4% YoY rise to ₹7.3 Cr. Standalone business mirrored...
**Financial Highlights:** Shalby's Q1 FY26 consolidated revenue rose 5.1% YoY to ₹303.4 Cr. However, EBITDA declined 11.6% to ₹48.5 Cr, leading to PBT dropping 25.5% to ₹22.7 Cr and PAT falling 47.9% to ₹7.7 Cr. Standalone revenue saw a modest 0.7% increase to ₹242.2 Cr, with EBITDA dipping 9.8% to...
1. Financial Highlights: Consolidated revenue rose 8.4% YoY to ₹270.2 Cr in Q4 FY25, while EBITDA declined 40.4% to ₹26.2 Cr, squeezing EBITDA margin to 9.7% from 17.6% last year. Consolidated PBT turned to a loss of ₹0.7 Cr versus a ₹21.8 Cr profit prior year. Net debt increased to...
**Financial Highlights:** Consolidated revenue reached ₹2,811 million in Q3 FY25, up 27.4% from ₹2,206 million in Q3 FY24. However, consolidated EBITDA fell to ₹393 million, down 16.1% year-over-year. Profit before tax (PBT) also showed a decline to ₹124 million, a 59.9% drop compared to ₹308 million in Q3 FY24. Standalone...